Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

56 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Gender differences in demographic and clinical characteristics of patients with opioid use disorder entering a comparative effectiveness medication trial.
Campbell ANC, Barbosa-Leiker C, Hatch-Maillette M, Mennenga SE, Pavlicova M, Scodes J, Saraiya T, Mitchell SG, Rotrosen J, Novo P, Nunes EV, Greenfield SF. Campbell ANC, et al. Among authors: novo p. Am J Addict. 2018 Sep;27(6):465-470. doi: 10.1111/ajad.12784. Epub 2018 Aug 14. Am J Addict. 2018. PMID: 30106494 Free PMC article. Clinical Trial.
Ethical and clinical safety considerations in the design of an effectiveness trial: A comparison of buprenorphine versus naltrexone treatment for opioid dependence.
Nunes EV, Lee JD, Sisti D, Segal A, Caplan A, Fishman M, Bailey G, Brigham G, Novo P, Farkas S, Rotrosen J. Nunes EV, et al. Among authors: novo p. Contemp Clin Trials. 2016 Nov;51:34-43. doi: 10.1016/j.cct.2016.09.006. Epub 2016 Sep 28. Contemp Clin Trials. 2016. PMID: 27687743 Free PMC article.
Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial.
Lee JD, Nunes EV Jr, Novo P, Bachrach K, Bailey GL, Bhatt S, Farkas S, Fishman M, Gauthier P, Hodgkins CC, King J, Lindblad R, Liu D, Matthews AG, May J, Peavy KM, Ross S, Salazar D, Schkolnik P, Shmueli-Blumberg D, Stablein D, Subramaniam G, Rotrosen J. Lee JD, et al. Among authors: novo p. Lancet. 2018 Jan 27;391(10118):309-318. doi: 10.1016/S0140-6736(17)32812-X. Epub 2017 Nov 14. Lancet. 2018. PMID: 29150198 Free PMC article. Clinical Trial.
Variants of opioid genes and response to treatment of opioid use disorder with buprenorphine-naloxone versus extended-release naltrexone in Caucasians.
Randesi M, Rotrosen J, Nunes EV, Lee JD, Novo P, Levran O, Ott J, Pavlicova M, Scodes J, Kreek MJ. Randesi M, et al. Among authors: novo p. Am J Drug Alcohol Abuse. 2020 Nov 1;46(6):761-768. doi: 10.1080/00952990.2020.1797064. Epub 2020 Aug 27. Am J Drug Alcohol Abuse. 2020. PMID: 32851876 Free PMC article. Clinical Trial.
Prior National Drug Abuse Treatment Clinical Trials Network (CTN) opioid use disorder trials as background and rationale for NIDA CTN-0100 "optimizing retention, duration and discontinuation strategies for opioid use disorder pharmacotherapy (RDD)".
Shulman M, Weiss R, Rotrosen J, Novo P, Costello E, Nunes EV. Shulman M, et al. Among authors: novo p. Addict Sci Clin Pract. 2021 Mar 6;16(1):15. doi: 10.1186/s13722-021-00223-z. Addict Sci Clin Pract. 2021. PMID: 33676577 Free PMC article. Review.
Implementation facilitation to introduce and support emergency department-initiated buprenorphine for opioid use disorder in high need, low resource settings: protocol for multi-site implementation-feasibility study.
McCormack RP, Rotrosen J, Gauthier P, D'Onofrio G, Fiellin DA, Marsch LA, Novo P, Liu D, Edelman EJ, Farkas S, Matthews AG, Mulatya C, Salazar D, Wolff J, Knight R, Goodman W, Hawk K. McCormack RP, et al. Among authors: novo p. Addict Sci Clin Pract. 2021 Mar 9;16(1):16. doi: 10.1186/s13722-021-00224-y. Addict Sci Clin Pract. 2021. PMID: 33750454 Free PMC article.
56 results